The Clinical Utility of F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.

PURPOSE

To evaluate the diagnostic performance and clinical utility of F-fluciclovine PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC).

METHODS

F-Fluciclovine scans of 165 consecutive men with BCR after primary definitive treatment with prostatectomy (n = 102) or radiotherapy (n = 63) were retrospectively evaluated. Seventy patients had concurrent imaging with at least one other conventional modality (CT (n = 31), MRI (n = 31), or bone scan (n = 26)). Findings from F-fluciclovine PET were compared with those from conventional imaging modalities. The positivity rate and impact of F-fluciclovine PET on patient management were recorded. In 33 patients who underwent at least one other PET imaging (F-NaF PET/CT (n = 12), Ga-PSMA11 PET/CT (n = 5), F-DCFPyL PET/CT (n = 20), and Ga-RM2 PET/MRI (n = 5)), additional findings were evaluated.

RESULTS

The overall positivity rate of F-fluciclovine PET was 67 %, which, as expected, increased with higher prostate-specific antigen (PSA) levels (ng/ml): 15 % (PSA < 0.5), 50 % (0.5 ≤ PSA < 1), 56 % (1 ≤ PSA < 2), 68 % (2 ≤ PSA < 5), and 94 % (PSA ≥ 5), respectively. One hundred and two patients (62 %) had changes in clinical management based on F-fluciclovine PET findings. Twelve of these patients (12 %) had lesion localization on F-fluciclovine PET, despite negative conventional imaging. Treatment plans of 14 patients with negative F-fluciclovine PET were changed based on additional PET imaging with a different radiopharmaceutical.

CONCLUSION

F-Fluciclovine PET/CT remains a useful diagnostic tool in the workup of patients with BCR PC, changing clinical management in 62 % of participants in our cohort.